The General Meeting was held to approve the proposed Placing, Subscription and Open Offer to raise £27.5 million through the issuance of 30,513,341 New Shares in the Company. In addition, the passing of the Resolutions means that the Strategic Collaboration between Sensyne Health and Phesi Inc, a US based specialist clinical trials data company, will become effective on 5 January 2021.
The full text of the Resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 14 December 2020 which is available on the Company’s website www.sensynehealth.com.
It is expected that Admission of the New Shares will become effective at 8.00 a.m. on 5 January 2021. Following Admission, the Company will have 159,084,855 Ordinary Shares of 10p in issue each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 08 December 2020.
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.